AU2002256092C1 - Controlled delivery of tetracycline compounds and tetracycline derivatives - Google Patents

Controlled delivery of tetracycline compounds and tetracycline derivatives Download PDF

Info

Publication number
AU2002256092C1
AU2002256092C1 AU2002256092A AU2002256092A AU2002256092C1 AU 2002256092 C1 AU2002256092 C1 AU 2002256092C1 AU 2002256092 A AU2002256092 A AU 2002256092A AU 2002256092 A AU2002256092 A AU 2002256092A AU 2002256092 C1 AU2002256092 C1 AU 2002256092C1
Authority
AU
Australia
Prior art keywords
tetracycline
release
tetracycline compound
mammal
controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002256092A
Other languages
English (en)
Other versions
AU2002256092A1 (en
AU2002256092B2 (en
Inventor
Robert A. Ashley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Collagenex Pharmaceuticals Inc
Original Assignee
Collagenex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Collagenex Pharmaceuticals Inc filed Critical Collagenex Pharmaceuticals Inc
Publication of AU2002256092A1 publication Critical patent/AU2002256092A1/en
Application granted granted Critical
Publication of AU2002256092B2 publication Critical patent/AU2002256092B2/en
Publication of AU2002256092C1 publication Critical patent/AU2002256092C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2002256092A 2001-04-05 2002-04-05 Controlled delivery of tetracycline compounds and tetracycline derivatives Ceased AU2002256092C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28185401P 2001-04-05 2001-04-05
US60/281,854 2001-04-05
PCT/US2002/010748 WO2002083106A1 (en) 2001-04-05 2002-04-05 Controlled delivery of tetracycline compounds and tetracycline derivatives

Publications (3)

Publication Number Publication Date
AU2002256092A1 AU2002256092A1 (en) 2003-04-17
AU2002256092B2 AU2002256092B2 (en) 2007-05-31
AU2002256092C1 true AU2002256092C1 (en) 2009-10-15

Family

ID=23079059

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002256092A Ceased AU2002256092C1 (en) 2001-04-05 2002-04-05 Controlled delivery of tetracycline compounds and tetracycline derivatives

Country Status (8)

Country Link
US (2) US20040115261A1 (cg-RX-API-DMAC7.html)
EP (2) EP2311440A1 (cg-RX-API-DMAC7.html)
JP (3) JP2004525955A (cg-RX-API-DMAC7.html)
KR (1) KR100982753B1 (cg-RX-API-DMAC7.html)
AU (1) AU2002256092C1 (cg-RX-API-DMAC7.html)
CA (1) CA2447008A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ529308A (cg-RX-API-DMAC7.html)
WO (1) WO2002083106A1 (cg-RX-API-DMAC7.html)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
CA2502986C (en) 2002-10-25 2011-08-23 Foamix Ltd. Cosmetic and pharmaceutical foam
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
EP2204168B1 (en) 2003-04-07 2015-01-14 Supernus Pharmaceuticals, Inc. Once daily formulations of tetracyclines
US8425936B2 (en) * 2003-07-21 2013-04-23 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005009365A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8313775B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005011707A1 (en) * 2003-07-25 2005-02-10 Warner Chilcott Company, Inc. A doxycycline metal complex in a solid dosage form
AU2004264356B2 (en) * 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1663169A4 (en) * 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In ANTIBIOTICS, ITS USE AND FORMULATION
CA2595481C (en) * 2005-01-21 2014-05-13 Warner Chilcott Company, Inc. A tetracycline metal complex in a solid dosage form
US7544373B2 (en) * 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20080242642A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7541347B2 (en) 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
EP3725324A1 (en) 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20080241197A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline dosage forms for the treatment of acne
WO2008121107A1 (en) * 2007-04-02 2008-10-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
CN101951936A (zh) 2008-02-26 2011-01-19 康奈尔大学 用于防止和治疗急性肾损伤的方法
PT2271348T (pt) 2008-03-28 2018-04-16 Paratek Pharm Innc Formulação de comprimido oral de composto de tetraciclina
WO2010017310A1 (en) 2008-08-06 2010-02-11 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
EP2875359A4 (en) 2012-03-30 2015-08-19 Charles R Drew University Of Medicine And Science COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLISM SYNDROME DISEASES
CA2868063A1 (en) * 2012-04-19 2013-10-24 Galderma S.A. Method of treating acne
PT106679B (pt) * 2012-11-27 2015-03-25 Hovione Farmaciencia Sa Formulações tópicas de tetraciclinas, sua preparação e usos
US20130303436A1 (en) 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
US10842802B2 (en) * 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
JP6480921B2 (ja) 2013-09-27 2019-03-13 コーネル ユニヴァーシティー コレステロール誘発性ミトコンドリア機能不全を治療するための芳香族カチオン性ペプチドの使用
WO2015089416A1 (en) 2013-12-12 2015-06-18 Cornell University Prolylhydroxylase/atf4 inhibitors for treating neural cell injury
EP3502132A1 (en) 2014-05-28 2019-06-26 Stealth BioTherapeutics Corp Therapeutic compositions including therapeutic small molecules and uses thereof
EP3501532A3 (en) 2014-05-28 2019-07-17 Stealth BioTherapeutics Corp Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
WO2016079590A1 (en) 2014-11-19 2016-05-26 Dr. Reddy's Laboratories Ltd. Modified release doxycycline composition
US10550093B2 (en) 2015-07-01 2020-02-04 The Research Foundation For The State University Of New York Third generation taxoids and methods of using same
EP4000690A1 (en) 2016-05-19 2022-05-25 Stealth BioTherapeutics Inc. Compositions and methods for the prevention and treatment of mitochondrial myopathies
MX2020012139A (es) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Composiciones y metodos para tratar rosacea y acne.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0195906A2 (en) * 1985-02-07 1986-10-01 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties
EP0464932A2 (en) * 1990-06-28 1992-01-08 The Research Foundation Of State University Of New York Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5532227A (en) * 1992-11-17 1996-07-02 The Research Foundation Of State University Of New York Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive glycosylation of different types of collagen and other proteins during diabetes
WO1998005340A1 (en) * 1996-08-01 1998-02-12 The Research Foundation Of State University Of Newyork Promotion of wound healing by chemically-modified tetracyclines
US5837696A (en) * 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA843403A (en) * 1970-06-02 E. Gaunt William Sustained release medicinal tablets
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US5589470A (en) * 1990-02-26 1996-12-31 Trustees Of Tufts College Reducing tetracycline resistance in living cells
US4935412A (en) 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
USRE34656E (en) 1983-12-29 1994-07-05 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
US4925833A (en) 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US5238686A (en) * 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US4837030A (en) * 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
US5277916A (en) * 1988-02-01 1994-01-11 F. H. Faulding & Co., Ltd. Tetracycline dosage form
US4980378A (en) * 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
ES2064564T3 (es) * 1989-09-21 1995-02-01 American Cyanamid Co Sistema de liberacion pulsatil de dosis unitaria diaria de minociclina.
JP3016587B2 (ja) * 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5308839A (en) * 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
US5188836A (en) * 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
US5770588A (en) * 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5223248A (en) * 1991-02-11 1993-06-29 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing antiplaque properties
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5167964A (en) * 1992-02-14 1992-12-01 Warner-Lambert Company Semi-enteric drug delivery systems and methods for preparing same
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5258371A (en) * 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US6043231A (en) * 1993-03-02 2000-03-28 The Research Foundation Of State Univ. Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5523297A (en) * 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5834449A (en) * 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
US5827503A (en) * 1996-08-08 1998-10-27 Collagenex Pharmaceuticals, Inc. Method and composition for treating periodontitis
US5789395A (en) * 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
JPH10190373A (ja) * 1996-12-20 1998-07-21 Fujitsu Ltd 増幅回路
US5792446A (en) * 1997-02-18 1998-08-11 Collagenex Pharmaceuticals, Inc. Delivery system for administering dentin-hypersensitivity-ameliorating compositions
US5773430A (en) * 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US5753711A (en) * 1997-03-18 1998-05-19 Collagenex Pharmaceuticals, Inc. Method for treatment of H. pylori
US5929055A (en) * 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US5908838A (en) * 1998-02-19 1999-06-01 Medics Pharmaceutical Corporation Method for the treatment of acne
DK1676579T3 (da) * 1998-05-08 2009-03-16 Univ Miami Anvendelse af sub-antimikrobielle tetracykliner til behandling af okulær rosacea
US6143506A (en) * 1998-08-13 2000-11-07 The Research Foundation Of State Of Ny Diagnostic method for detection of periodontitis or peri-implantitis
US6015804A (en) * 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) * 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US5998390A (en) * 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
US6914057B1 (en) * 1998-09-28 2005-07-05 The Research Foundation Of State University Of New York Inhibitor of cataract formation
CA2343038A1 (en) * 1998-09-28 2000-04-06 Maria Emanuel Ryan A novel inhibitor of cataract formation
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
PL205109B1 (pl) * 1998-11-02 2010-03-31 Elan Pharma Int Ltd Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie
WO2000028983A1 (en) * 1998-11-18 2000-05-25 Collagenex Pharmaceuticals, Inc. Novel 4-dedimethy laminotetra cycline derivatives
US6946453B2 (en) * 1998-11-18 2005-09-20 Collagenex Pharmaceuticals, Inc. 4-dedimethylaminotracycline derivatives
US6506740B1 (en) * 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
WO2000059481A1 (en) * 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
DE10004572A1 (de) * 2000-02-02 2001-08-09 Boehringer Ingelheim Pharma Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2400818C (en) * 2000-02-24 2009-01-06 Advancis Pharmaceutical Corporation Antibiotic and antifungal compositions
US6730320B2 (en) * 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6638532B2 (en) * 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US7211267B2 (en) * 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
WO2003088906A2 (en) * 2002-04-16 2003-10-30 Collagenex Pharmaceuticals, Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
CN100355830C (zh) * 2003-02-28 2007-12-19 日本瑞翁株式会社 弹性体组合物和压敏粘合剂组合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0195906A2 (en) * 1985-02-07 1986-10-01 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties
EP0464932A2 (en) * 1990-06-28 1992-01-08 The Research Foundation Of State University Of New York Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines
US5532227A (en) * 1992-11-17 1996-07-02 The Research Foundation Of State University Of New York Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive glycosylation of different types of collagen and other proteins during diabetes
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
WO1998005340A1 (en) * 1996-08-01 1998-02-12 The Research Foundation Of State University Of Newyork Promotion of wound healing by chemically-modified tetracyclines
US5837696A (en) * 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth

Also Published As

Publication number Publication date
EP2311440A1 (en) 2011-04-20
KR20040002896A (ko) 2004-01-07
US20110262542A1 (en) 2011-10-27
JP2010047617A (ja) 2010-03-04
NZ529308A (en) 2005-03-24
WO2002083106A1 (en) 2002-10-24
KR100982753B1 (ko) 2010-09-16
EP1383483A4 (en) 2006-08-09
EP1383483A1 (en) 2004-01-28
JP2004525955A (ja) 2004-08-26
US20040115261A1 (en) 2004-06-17
AU2002256092B2 (en) 2007-05-31
CA2447008A1 (en) 2002-10-24
JP2011157396A (ja) 2011-08-18

Similar Documents

Publication Publication Date Title
AU2002256092C1 (en) Controlled delivery of tetracycline compounds and tetracycline derivatives
AU2002256092A1 (en) Controlled delivery of tetracycline compounds and tetracycline derivatives
JP2676080B2 (ja) 非抗バクテリア性テトラサイクリン組成物
EP1119362B1 (en) Use of tetracycline derivatives to enhance interleukin-10 production
US8394405B2 (en) Once daily formulations of tetracyclines
EP0586020A1 (en) Tetracyclines alone or in combination with NSAID for treating tissue destruction
CN101460177A (zh) 用于抑制细菌芽孢的非抗菌四环素剂型的应用
KR20040094833A (ko) 비-항균성 테트라사이클린 동족체의 용도 및 박테리아외독소의 치료를 위한 이의 제형
US20050282786A1 (en) Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations
MXPA06010404A (es) Metodo para tratar la estenosis aortica con formulaciones de tetraciclina no anti-bacterianas.
WO2004054509A2 (en) Tetracyclines as anti-fungal agents for treatment of ringworm

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 APR 2009.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 APR 2009

MK14 Patent ceased section 143(a) (annual fees not paid) or expired